Feb. 12, 2025 — Orchestra BioMed Holdings, a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, recently made an oral presentation of data on the benefits of atrioventricular interval modulation (AVIM) therapy on patients with diastolic dysfunction at the Technology and Heart Failure Therapeutics (THT) 2025 Conference in Boston, Mass.